Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 14 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 7% above its 52-week low
None of the 29 investors followed here reported a position in CLDI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CLDI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 11, 2025 | Camaisa AllanDirector | Sale at price 1.46 per share. | 850 | $1.24K |
| Aug 20, 2025 | Poma Eric E. Ph.D.Chief Executive Officer | Purchase at price 2.00 per share. | 25K | $50.00K |
| Aug 20, 2025 | Schoeneck James ADirector | Purchase at price 2.00 per share. | 75K | $150.00K |
| Aug 20, 2025 | Jackson Andrew CChief Financial Officer | Purchase at price 2.00 per share. | 2.5K | $5.00K |
| Aug 20, 2025 | Leftwich ScottDirector | Purchase at price 2.00 per share. | 125K | $250.00K |
| Dec 30, 2024 | Stewart Alan RDirector | — | 12.8K | — |
| Dec 30, 2024 | Leftwich ScottDirector | — | 11.7K | — |
| Dec 16, 2024 | Camaisa AllanChief Executive Officer | Sale at price 1.62 per share. | 10K | $16.20K |
| Sep 25, 2024 | Camaisa AllanChief Executive Officer | Stock Award(Grant) at price 1.15 per share. | 70.2K | $80.68K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.8 | -22.1 | -69.9 | -0.8 | -21.9 | -8.1 | -39.7 | -18.3 | -20.1 | -18.3 | −95.3% | ||
| 2025 | -34.1 | 16.1 | -35.7 | -14.7 | -27.5 | -34.3 | 159.1 | -76.9 | -7.9 | 1.3 | -1.9 | -22.5 | −91.5% |
| 2024 | -47.0 | -25.4 | -5.4 | -65.5 | -2.6 | 5.3 | -21.5 | -27.4 | 0.0 | 3.5 | 79.7 | -45.8 | −92.4% |
| 2023 | 0.8 | 0.1 | 0.1 | 0.0 | 1.4 | 0.8 | 0.4 | -12.8 | -63.8 | -34.4 | -3.7 | -28.1 | −85.2% |
| 2022 | 0.2 | 0.2 | 0.4 | 0.2 | -0.1 | 0.4 | 0.2 | 0.4 | -1.5 | 1.0 | 1.4 | 0.8 | +3.7% |
| 2021 | -0.1 | −0.1% |
No analyst coverage for this instrument.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.